{
    "Trade/Device Name(s)": [
        "VIDAS NT-proBNP Assay"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K073091",
    "Predicate Device Reference 510(k) Number(s)": [
        "K022516"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "February 04, 2008",
    "Summary Letter Received Date": "February 05, 2008",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1117"
    ],
    "Regulation Name(s)": [
        "B-type natriuretic peptide test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "N-terminal fragment of B-type natriuretic peptide (NT-proBNP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (lithium heparin)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "VIDAS instruments"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-Linked Fluorescent Assay (ELFA)",
        "Immunoassay"
    ],
    "Methodologies": [
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for VIDAS NT-proBNP Assay, an automated quantitative immunoassay on VIDAS instruments for NT-proBNP to aid in diagnosis of suspected congestive heart failure.",
    "Indications for Use Summary": "Automated quantitative test on VIDAS instruments to determine NT-proBNP in human serum or plasma (lithium heparin), used as an aid in diagnosis of suspected congestive heart failure.",
    "fda_folder": "Clinical Chemistry"
}